Jazz, Hikma deal

Jazz granted Hikma rights to market an authorized generic version of narcolepsy drug Xyrem sodium oxybate starting on Jan. 1, 2023. The agreement settles patent litigation between Jazz and Roxane Laboratories Inc., which Hikma acquired in 2015.

Hikma will initially have rights to market its product through Xyrem's REMS for six months, and may opt to extend the term for up to five years. Jazz is eligible for royalties, which would increase if Hikma extends the term beyond one year...